Ther­a­peu­tic­sMD flags “de­fi­cien­cies” in NDA; CRUK, NCI col­lab­o­rate on RAS in­hibitor re­search

→ Bo­ca Ra­ton, FL-based Ther­a­peu­tic­sMD $TXMD is flag­ging some se­ri­ous prob­lems for their new drug ap­pli­ca­tion at the FDA. In a state­ment to­day the com­pa­ny said reg­u­la­tors had iden­ti­fied “de­fi­cien­cies” in their ap­pli­ca­tion, though it’s not ex­act­ly sure what those de­fi­cien­cies are. They’re seek­ing a mar­ket­ing ap­proval for TX-004HR, “an in­ves­ti­ga­tion­al bio-iden­ti­cal 17β-estra­di­ol vagi­nal soft­gel cap­sule for the treat­ment of mod­er­ate-to-se­vere vagi­nal pain dur­ing sex­u­al in­ter­course (dys­pare­u­nia), a symp­tom of vul­var vagi­nal at­ro­phy (VVA) in post­menopausal women.” The biotech says it plans to find out what the de­fi­cien­cies are and re­solve them AS­AP.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER